Sionna Therapeutics posts higher-than-expected Q3 net loss on restructuring costs

Overview

• Biopharmaceutical firm's Q3 net loss widened, missing analyst expectations

• Operating expenses rose yr/yr due to development and restructuring costs

• Company implemented 46% workforce reduction to focus on lead CF program

Outlook

• Sionna plans to start AscenSION CF Phase 2 trial in first quarter of 2027

• Company expects current cash position to fund operations into second half of 2029

• Company focusing resources on SION-451 + SION-2222 development following workforce reduction

Result Drivers

• R&D AND RESTRUCTURING COSTS - Higher research and development expenses and restructuring costs, including workforce reduction, drove increased operating expenses in Q3

• FOCUS ON LEAD PROGRAM - Company concentrated resources on advancing SION-451 + SION-2222 dual combination for cystic fibrosis, following pipeline reprioritization

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Sionna Therapeutics, Inc. is $6.00, about 68.1% above its November 9 closing price of $3.57

Reuters Recommended Reads

• Nov 9 - Maze Therapeutics Q3 results miss estimates on higher R&D spending

• Nov 9 - Trevi Therapeutics Q3 net loss widens on higher R&D costs

• Nov 9 - Structure Therapeutics Q3 loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)